A new formulation of a selective serotonin receptor inhibitor (SSRI)-low-dose mesylate of paroxetine (LDMP)-shows promise for reducing vasomotor symptoms of menopause, according to results of two studies presented at the North American Menopause Society (NAMS) conference.Contemporary OB/GYN Staff...
Selective serotonin reuptake inhibitors (SSRIs) were recently approved by the FDA to treat vasomotor symptoms associated with menopause. No prior study has directly examined whether fracture risk is increased among perimenopausal women w... YH Sheu,A Lanteigne,T Stürmer,... - 《Injury Prevention ...
Selective serotonin reuptake inhibitors (SSRIs) were recently approved by the FDA to treat vasomotor symptoms associated with menopause. No prior study has directly examined whether fracture risk is increased among perimenopausal women who initiate SSRIs or among a population of women without mental ...
The article reports an alternative option to hormone therapy in controlling vasomotor symptoms during menopause. Studies have shown selective serotonin reuptake inhibitors (SSRIs) to be more effective ...
and M. Williams, The efficacy and tolerability of SSRI/SNRIs in the treatment of vasomotor symptoms in menopausal women: a systematic review. J Am Assoc Nurse Pract, 2015. 27(1): p. 54-61.Handley AP and Williams M. The efficacy and tolerability of SSRI/SNRIs in the treatment of ...